توكل على الله
عضو نشط
- التسجيل
- 10 سبتمبر 2009
- المشاركات
- 790
ابوعبدالله تقبل الله منا ومنك صالح الاعمال قال تعالى --------الفجر وليالى العشر----------صدق الله العظيم -----------شدوا الهمه مابقى شئ اعاده الله على الجميع بالخير واليمن والبركات
دورة المؤشرنت للتحليل الفني
50 دينار كويتي
سهم طيب عليه اخبار حلوووووووه والله يرزقكم اجمعيين
GENOVA BIOTHERAP INC (GVBP.OB)
Press Release
Source: GENova Biotherapeutics, Inc.
On Friday September 4, 2009, 9:00 am EDT
Buzz up! 0 Print
NEW YORK, NY, Sept. 4 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB - News) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Dr. John Savin as its Vice President.
Dr. Savin will work closely with the CEO to direct GENova's growth in its business of identifying and acquiring potential drug targets and then subsequently outsourcing them to partners who can successfully usher them through clinical trials and then bring them to market.
"I am honoured to guide GENova as it positions itself as a leader in the expeditious development of innovative drugs," said Dr. Savin. "I am confident that the GENova business model will deliver new and effective therapies for patients while maximizing value for shareholders."
About John Savin, B.Sc, Ph.D., MBA
Mr. Savin builds on his 20 years experience in marketing and finance to provide strategic direction in the commercialisation and funding of innovative science on behalf of high-potential companies. His previous role was CEO of Physiomics, a systems biology company that he founded. Physiomics entered collaborations with companies like Bayer and Cyclacel, and developed a sophisticated product to optimize cancer therapeutic development. His company listed on AIM in 2004.
Prior to that, Savin worked for investment bank Gerrard Group as a pharmaceutical and biotechnology investment analyst, soon becoming a Director and a top-10-ranked City analyst. In this role, he worked with corporate finance on venture capital, many IPOs, secondary fund raising, restructuring and due diligence. Other experience includes being a Senior Consultant working at Board level with Glaxo, Zeneca, the MRC and Cabinet Office and DTi looking at issues such as the commercialization of humanized monoclonals and the strategic impact of the human genome project; and serving as International Product Manager for Pharmacia Biotech (Sweden) and Amersham International (UK). In addition to his current consulting role, Savin also writes investment research on listed biotechnology and medical devices companies. He has a B.Sc in Bioscience and Chemistry, an M.B.A. in Strategic Management, and a Ph.D in Organic Chemistry.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: www.genovabio.com.
انشالله راح نشوف اسبوع حافل باذن الله عزوجل
مساكم الله بالخير يالربع
والله وبدون مجامله من اروع المواضيع بالمنتدى ومني لكم هديه وان شاء الله يرتفع السهم وابي رايكم فيه stwg واغلاق السهم 0.14 وتداول5,077,660سهم وتقبلوا مروري
الاول دخووول 72 والثاني 295
دورة المؤشرنت للتحليل الفني
50 دينار كويتي